Clinical trials: Duloxetine
Urinary Stress Incontinence
Biomechanical Effects of Duloxetine on Bladder and Sphincter Muscle Function in Women in Pure Genuine Stress Incontinence
Double-blind placebo-controlled study of the biomechanical effects of duloxetine compared with placebo in the treatment of women with pure genuine stress incontinence
- Trial name
- NCT00190567
- Testing
- duloxetine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Eli Lilly and Company
Central Sensitisation, Fibromyalgia
The Effect of Central Sensitization on Treatment Response in Patients With Fibromyalgia
Central sensitization (CS) is as increased response to normal or sub-threshold stimuli of central nervous system and its close relationship with fibromyalgia has been demonstrated in several studies.
- Trial name
- NCT05020600
- Testing
- Duloxetine, Pregabalin, Amitriptyline
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Marmara University
Major Depressive Disorder
Early Versus Delayed Switch in Medication in Patients With Major Depressive Disorder
This study investigates two different approaches to the change in antidepressant treatment when an initial treatment is not effective: early intervention or delayed intervention. Two hypothesis will be tested: 1.
- Trial name
- NCT00810069
- Testing
- Duloxetine Hydrochloride, Escitalopram
- Where
- 60 sites in Denmark, France and 9 more
- Volunteers
- 840 people
- Sponsor
- Eli Lilly and Company
Stress Urinary Incontinence
To Evaluate the Safety of Duloxetine in Patients With Stress Urinary Incontinence
The patients are being followed in this study to determine the safety of taking the medication Duloxetine for a long period of time. The patients participating in this study suffer from Stress Urinary Incontinence.
- Trial name
- NCT00190645
- Testing
- Duloxetine
- Where
- 2 sites in United States, Canada
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Chronic Pain
Comparing Effectiveness of Duloxetine and Desipramine in Patients With Chronic Pain: A Pragmatic Trial Using Point of Care Randomization
Over 100 million Americans suffer from chronic pain resulting in annual cost of roughly $635 billion. Limited treatments are available for this widespread disease.
- Trial name
- NCT03548454
- Testing
- Duloxetine, Desipramine
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Stanford University
Depression
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued duloxetine in the treatment of patients with treatment resistant depression (TRD).
- Trial name
- NCT01309945
- Testing
- Duloxetine, BMS-820836
- Where
- 84 sites in United States, Canada and 4 more
- Volunteers
- 889 people
- Sponsor
- Bristol-Myers Squibb
Drug-induced Liver Injury
Rechallenge, Potential Drug Induced Liver Injury (Kaiser)
Drug re-administration or rechallenge should be avoided after drug-induced liver injury (DILI) to avoid recurrent and fatal injury. Rechallenge outcomes vary considerably by drug and patient subjects.
- Trial name
- NCT01584765
- Testing
- Prescription drugs with known hepatotoxicity
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Depressive Disorder, Treatment-Resistant
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
The purpose of this study is to assess the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant (active comparator) plus intranasal placebo in delaying relapse of depressive symptoms…
- Trial name
- SUSTAIN-1 (NCT02493868)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 155 sites in United States, Belgium and 13 more
- Volunteers
- 719 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Depression
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
To assess the long-term safety and tolerability of oral OPC-34712 (brexpiprazole), given in addition to an FDA approved antidepressant (ADT) for the treatment of adults with Major Depressive Disorder (MDD)
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- Orion (NCT01360866)
- Testing
- OPC-34712, Escitalopram, Fluoxetine
- Where
- 142 sites in United States, Canada and 9 more
- Volunteers
- 2,944 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
Multi-Country Observational Study to Collect the Frequency of Sexual Dysfunction With Antidepressant Treatment, Either With SSRIs or Duals at 8 Weeks and 6 Months
In usual clinical conditions, depressed patients with no sexual dysfunction, after signing their consent for the dissemination of their clinical information will begin their treatment with any SSRI or a Dual antidepressant as per…
- Trial name
- NCT00561509
- Testing
- SSRIs, Dual antidepressants
- Where
- 57 sites in Austria, China and 11 more
- Volunteers
- 1,626 people
- Sponsor
- Eli Lilly and Company
Drug Effect
Comparison of Duloxetine Versus Pregabalin
Chronic post mastectomy pain syndrome (PMPS) is a chronic post-surgical neuropathic pain following breast cancer surgeries and lasting more than three months after surgeries.
- Trial name
- NCT04727502
- Testing
- Duloxetine, Pregablin
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute, Egypt
Major Depressive Disorder, Dysthymic Disorder
Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults
The goal of this open-administration treatment study of citalopram (or duloxetine) is to evaluate the effect of antidepressant medication on treating the syndrome of "frailty" in older adults with depressive symptoms.
- Conditions
- Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder, NOS
- Trial name
- NCT01973283
- Testing
- Antidepressant Medication
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- New York State Psychiatric Institute
Pain
Pain Prevention and Treatment Through the Enhancement of the Anti-nociceptive Component of Pain Modulation Profiles
To utilize the plasticity of the central pain pathways in order to (i) shift individuals with a pro-nociceptive pain modulation profile towards an anti-nociceptive one, and (ii) assess its relevance in minimizing pain-derived…
- Trial name
- NCT02020122
- Testing
- Duloxetine, Pregabalin
- Where
- Israel
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
Major Depressive Disorder (MDD)
A Phase II Study to Evaluate NH102 for Depression
This study is a multicenter, randomized, double-blind, double-dummy, parallel-group, dose-finding Phase II clinical trial with placebo and active comparator duloxetine .
- Trial name
- NH102-21 (NCT06842992)
- Testing
- NH102, Duloxetine Hydrochloride Enteric-coated Capsule
- Where
- 24 sites in China
- Volunteers
- 243 people
- Sponsor
- Jiangsu Nhwa Pharmaceutical Co., Ltd.
Multiple Sclerosis
A Study to Test the Use of Duloxetine for Pain in MS
Many patients with Multiple Sclerosis experience pain that is caused by the effects of MS on the nervous system. The purpose of this study is to see if an investigational drug (Duloxetine) will reduce pain in subjects with MS.
- Trial name
- NCT00457730
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Brown, Theodore R., M.D., MPH
Pain, Osteoarthritis
Brain Morphometry in OA Patients Treated With Duloxetine
This is a two week,single-blind study evaluating pain response and changes in brain imaging upon treatment with placebo in people with knee OA.
- Trial name
- NCT02903238
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Northwestern University
Chronic Low-back Pain
Algorithm-informed Decision-making to Advance Pain Treatment
Researchers are exploring how certain personal factors, such as symptoms, health history, and lifestyle, may help predict which treatments will work best for someone.
- Trial name
- ADAPT (NCT07731750)
- Testing
- Algorithmically informed randomization (taking into account phenotypes), Physical Therapy (PT) and Exercise, Cognitive-Behavioral Therapy for Pain (PRISM-CBT)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of Michigan
Fibromyalgia Syndrome
Study on the Efficacy and Safety of Tongluo Kaibi Tablets in the Treatment of Fibromyalgia Syndrome
Fibromyalgia is a chronic, disabling musculoskeletal pain disorder. Pregabalin is the sole pharmaceutical agent approved for the treatment of fibromyalgia in China.
- Trial name
- NCT07708948
- Testing
- Tongluo Kaibi Tablet, Pregabalin capsule
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Qutenza, Duloxetine
Qutenza Versus Duloxetine in Chemotherapy-induced Peripheral Neuropathy (CIPN)
The primary objective is to determine whether in patients with CIPN pain, treatment with Qutenza has the same effect as treatment with duloxetine 60 mg daily.
- Conditions
- Qutenza, Duloxetine, Chemotherapy-induced Peripheral Neuropathy, CIPN - Chemotherapy-Induced Peripheral Neuropathy
- Trial name
- QULOX (NCT05560516)
- Testing
- Qutenza, Duloxetine
- Where
- Netherlands
- Volunteers
- 102 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)